Potential Efficacy of Shiunko for Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody-Induced Skin Fissure: A Single Institutional Case Series

• Published in: Integrative cancer therapies 2024-01, Vol.23, p.15347354231225962-15347354231225962
• Main Authors: Okunaka, Mashiro, Kotani, Daisuke, Mishima, Saori, Nakamura, Maho, Kawazoe, Akihito, Bando, Hideaki, Yoshino, Takayuki, Shitara, Kohei
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - adverse effects; Antineoplastic Agents - adverse effects; Cetuximab - adverse effects; Colonic Neoplasms - drug therapy; Colorectal Neoplasms - drug therapy; Drugs, Chinese Herbal - therapeutic use; ErbB Receptors - metabolism; Female; Humans; Male; Middle Aged; Quality of Life; Retrospective Studies
• ISSN: 1534-7354; 1552-695X
• DOI: 10.1177/15347354231225962

Anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb) is the key drug for / V600E wild-type metastatic colorectal cancer (mCRC). However, anti-EGFR mAb-induced skin fissures often affect a patient's quality of life. Shiunko, a traditional Japanese topical herbal medicine, is used for burns and dermatitis and may potentially have wound-healing effects. Herein, we report cases of patients with mCRC who were treated with Shiunko for anti-EGFR mAb-induced skin fissure. We retrospectively reviewed consecutive patients with mCRC who received an anti-EGFR mAb-containing regimen and were treated with Shiunko twice a day for skin fissures at the National Cancer Center Hospital East between March 2022 and December 2022. Skin fissures were assessed at baseline and at every visit until 28 days after Shiunko initiation according to CTCAE v5.0. Among the 11 patients, 5 patients were female; the median age was 61 (range, 43-79) years. The median treatment duration with anti-EGFR mAb before Shiunko initiation was 13.1 (range, 6-52) weeks. Skin moisturizer and topical steroids were applied for skin fissures in 11 and 5 patients, respectively. All patients had grade 2 skin fissures at baseline of Shiunko initiation. Two weeks after Shiunko initiation, complete recovery was noted in 4 patients and improvement to grade 1 was noted in 6 patients. There were no Shiunko-related adverse events. Ten patients continued anti-EGFR mAb treatment until disease progression, while 1 patient discontinued anti-EGFR mAb treatment due to severe eruptions. Shiunko could be a treatment option for anti-EGFR mAb-induced skin fissure. Further studies are warranted to investigate the efficacy and safety of Shiunko for anti-EGFR mAb-induced skin fissure.